🔄 AMGN Rolls Its Deep-ITM $310 Calls Out to October — A Dividend-Timing Move, Not a Fresh Bullish Bet

📅 July 30, 2026 | 🔥 Unusual Activity Detected

✅ UPDATE — July 31, 2026 pre-market: the roll is CONFIRMED. October $310 open interest rose 224 → 2,418 (+2,194) while August $310 fell 2,217 → 491 (−1,726) — the two legs moved in opposite directions exactly as a roll requires. The bearish-diagonal alternative is ruled out. See the ✅ RESOLVED box below.

---

🎯 The Quick Take

Someone just rolled a ≈2,184-contract deep-in-the-money $310 call position in Amgen (AMGN) out from August to October — buying the Oct-16 $310 calls while selling the Aug-21 $310 calls, both roughly $72 in the money with spot at $382.08. Each leg carries ≈$16M of notional premium, but because it's a same-strike calendar roll, the actual net cash outlay is tiny — ≈$0.4M. This isn't a whale betting big on AMGN going up — it's someone maintaining an existing long-call position and pushing it past Amgen's August 24 ex-dividend date to dodge early-assignment risk. Neutral-to-mildly-bullish housekeeping, not conviction.

---

📊 Company Overview

Amgen (AMGN) is one of the world's largest biotechnology companies, in the Health Care / Biotechnology-Pharmaceuticals sector:

• Market Cap: ≈$199 billion (StockAnalysis market cap)
• Current Price: ≈$382-385 (last confirmed close $376.04 on July 24) (StockAnalysis)
• 52-Week Range: $269.77 – $391.29 (StockAnalysis; FinanceCharts)
• YTD 2026 Total Return: a modest ≈+0.95% to +3.27% (FinanceCharts)
• 12-Month Total Return: ≈+26.6% (FinanceCharts)
• Key franchises: Repatha (PCSK9/cardiovascular), Prolia/Evenity (bone health), Tezspire (severe asthma), Uplizna, and — the story everyone's watching — MariTide, Amgen's once-monthly GIPR-antagonist/GLP-1 obesity drug racing to catch Lilly and Novo Nordisk in the weight-loss market.

Amgen just isn't a meme stock — it's a steady, dividend-paying pharma major (currently paying $2.52/quarter) whose big multi-hundred-billion-dollar swing factor (MariTide) doesn't have decisive data until early 2027. That backdrop matters for reading today's options print correctly.

---

💰 The Option Flow Breakdown

📊 What Just Happened

Both legs printed at 11:47:32 ET as a listed multi-leg combo (an electronic calendar-roll order, filled together, not two separate random trades) at the $310 strike — about $72 in the money with AMGN at $382.08:

🔄 Structure tag: deep-ITM $310 call calendar roll — a listed multi-leg combo, not a block cross and not a lit sweep. Reading it as two separate whale bets would miss the point entirely.

The math that matters:

• 💸 Both strikes are ≈$72 in the money. The Oct call trades at $74.96 (only $2.88 of time value), the Aug call at $73.14 (only $1.06 of time value). When a call is priced almost entirely on intrinsic value like this, it behaves like owning the stock on leverage — a classic "stock replacement" position, not a lottery ticket.
• 💰 Net cost of the roll: ($74.96 − $73.14) × 2,184 × 100 = ≈$397,000, or ≈$0.4M. The two $16M "premium" figures are gross notional per leg — almost all of that is intrinsic value simply changing hands between the same underlying long position, not new risk capital being committed.

✅ RESOLVED — It Was a Roll. Both Legs Confirmed, Exactly as Predicted.

We could not prove the August leg was a close from the tape alone — size ≈ OI is the signature of closing, but only next-day open interest settles it. We named the test in advance: August OI should fall by ≈2,184 while October OI should rise by ≈2,184; if August OI rose instead, this was a bearish diagonal, not a roll. The July 31 pre-market OPRA snapshot came back on the roll side of that test:

The two legs moved in opposite directions, which is the whole point. Contracts are only created when a position opens and only destroyed when one closes. October open interest rose by 2,194 — essentially the full print — so the far leg is a clean, complete fresh open. August open interest fell by 1,726, dropping ≈78% of the strike's entire position. A print landing on a shrinking strike cannot have opened new August exposure. The bearish-diagonal alternative is ruled out.

One honest nuance on the August leg. OI fell by 1,726, not the full 2,184 — so roughly 79% of the closing leg genuinely retired contracts, while the remaining ≈458 changed owners rather than being extinguished. In plain terms: most of the counterparty was letting the position go, but a minority simply took over the other side. That does not change the structure — this desk's August exposure is gone either way — it just means the strike as a whole shrank slightly less than our print size. No cancellations appeared on the tape.

Net effect, confirmed: the desk closed its near-dated deep-in-the-money August calls and re-established the same $310 exposure in October. This is maintenance of an existing long position, not new directional risk — precisely the financing/dividend-timing roll described below.

🤓 What This Actually Means — Plain English

Think of this less like a "trade" and more like refinancing a mortgage. Someone already owned a big chunk of deep-in-the-money AMGN calls at the $310 strike expiring August 21. Rather than let that position run into expiration, they sold the August calls and simultaneously bought the same $310 strike two months further out (October 16) — a calendar roll.

Why roll instead of just holding? Two deep-ITM-specific reasons line up perfectly here:

1. Dividend timing / early-assignment risk. Amgen goes ex-dividend August 24, 2026 paying $2.52/share (StockScan dividend history). The old August 21 calls expired just 3 calendar days before that ex-date — deep-ITM calls carry real early-assignment risk right before a dividend, because whoever is short those calls has an incentive to exercise and capture the payout. Rolling out to October sidesteps that entire mess.
2. Stock replacement, extended. Because both strikes are almost pure intrinsic value (only $1-3 of time premium), this position behaves like owning ≈218,400 shares (2,184 contracts × 100) on leverage, not like a speculative options bet. Rolling it out just extends the same exposure for two more months at almost no incremental cost.

Why this is neutral, not a fresh bullish signal: the trader already had this long exposure — they didn't add a single new dollar of directional risk today. This is portfolio maintenance / financing, the options equivalent of renewing a lease, not a new bet that AMGN is about to rip higher. If anything, it's mildly bullish only in the sense that they chose to keep the long exposure alive rather than let it expire and walk away.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

AMGN has had a quiet 2026 by its own standards — YTD total return is only ≈+0.95% to +3.27% (FinanceCharts), even though the trailing 12 months are up a healthy ≈+26.6%. The stock is sitting near the top of its 52-week range ($269.77 – $391.29), just below its March 2 high of $391.29.

Gamma-Based Support & Resistance Analysis

Current Price: ≈$384.65

Fair warning: AMGN's gamma positioning is thin right now — there's no single strike where dealer gamma is heavily concentrated the way you'd see in a mega-cap like AMD or NVDA. That itself is informative: this isn't a name where market makers are pinning price to a specific level today.

That said, the largest gamma clusters in the chain sit:

• 🟠 Resistance (call-gamma leaning): $400 and the far-out $440 strike carry the biggest call-gamma weight in the visible chain — those would act as overhead "speed bumps" only if AMGN mounts a meaningful rally.
• 🔵 Support (put-gamma leaning): $330 and $300 show the largest put-gamma clusters below spot — a genuine pullback zone, but both are well below where AMGN trades today.
• The $310 strike where today's roll sits shows modest, mixed gamma (put-leaning) — it's simply where this particular long position happens to live, not a magnet level the whole market is fighting over.

Because the gamma map is this thin, lean more on the implied-move cone below for actionable near-term ranges.

Implied Move Analysis

Options market pricing for upcoming expirations (spot ≈$384.70):

• 📅 Weekly (Jul 31 - 1 day): ±$7.73 (±2.0%) → Range: $376.97 - $392.43
• 📅 Monthly OPEX (Aug 21 - 22 days, same day as the closed leg): ±$36.59 (±9.5%) → Range: $348.11 - $421.29
• 📅 Quarterly Triple Witch (Sep 18 - 50 days): ±$47.62 (±12.4%) → Range: $337.08 - $432.32
• 📅 LEAPS (Jun 17, 2027 - 322 days): ±$110.44 (±28.7%) → Range: $274.26 - $495.14

Translation for regular folks: the options market isn't pricing a huge near-term move — just ±2% by tomorrow. But zoom out to the August 21 OPEX (the date the closed leg would have expired) and the market is pricing a ±9.5% swing, which lines up with Q2 earnings on August 4 sitting right in that window. The roll pushes exposure past both the earnings print AND the ex-dividend date into a calmer runway through October 16.

---

🎪 Catalysts

✅ Already Happened (Last ≈3 Months)

• Q1 2026 earnings (April): revenue +6% YoY to $8.6B, beat on both lines, FY2026 guidance raised to $37.1B-$38.5B revenue and $21.70-$23.10 non-GAAP EPS (Amgen press release; SEC 8-K).
• 16 products delivered double-digit growth, led by Repatha +34% YoY to $876M and Evenity +27% YoY to $562M (Yahoo/Zacks), while Prolia fell -34% YoY on biosimilar erosion.
• MariTide Phase 2 long-term data: the large majority of participants maintained weight loss for an additional 52 weeks on a lower monthly dose, with low nausea/vomiting and no new safety signals — full results published in the New England Journal of Medicine.

🔜 Upcoming (Next ≈6 Months)

• Q2 2026 earnings — Tuesday, August 4, 2026, after the close (StockTitan webcast notice). Consensus is calling for ≈$9.43B revenue and ≈$5.60-$5.61 EPS — a rare expected YoY EPS decline of ≈7% (Yahoo Finance preview; WallStreetZen). This falls squarely inside the window the August $310 short leg would have covered — one more reason to roll past it.
• Ex-dividend — August 24, 2026; pay date September 11, 2026; $2.52/share (StockScan dividend history). This is the direct trigger for today's roll — the old August 21 calls expired just 3 days before this date.
• MariTide Phase 3 (MARITIME program) — the real long-term catalyst. MARITIME-1 (obesity), MARITIME-2 (obesity + T2D), plus cardiovascular/heart-failure/sleep-apnea sub-studies are all enrolling, but the primary MARITIME-1 readout isn't expected until ≈the beginning of 2027 — meaning there is no Phase 3 obesity data due in 2026 (FierceBiotech; Amgen MARITIME overview). Anything traders hear before then will just be enrollment/timeline commentary on earnings calls.
• Analyst sentiment: consensus rating is Hold, with a mean price target of ≈$352.73 — below today's ≈$382-385 spot, implying the Street sees AMGN as roughly fairly valued pending MariTide de-risking (WallStreetZen; StockAnalysis forecast).

---

🎲 Price Targets & Probabilities

Because this is a maintenance roll rather than a fresh directional bet, we're not treating it as "the market's forecast" the way a big lit sweep would be. Using the gamma clusters and implied-move cone as the honest baseline through October 16 (the new expiration):

📈 Bull Case (25% probability) — Target: $421-$432

Q2 earnings beat expectations on August 4, MariTide enrollment/timeline commentary is upbeat, and AMGN grinds up toward the $400-$440 call-gamma cluster and the top of the Sep/Oct implied-move range.

🎯 Base Case (50% probability) — Target: $348-$421 (the Aug OPEX implied-move range)

AMGN chops through earnings and the ex-dividend date roughly in line with the ±9.5% priced move, with the $310 roll simply carrying the existing long exposure through the noise. This is the scenario the roll itself is agnostic to.

📉 Bear Case (25% probability) — Target: $337-$348

A soft Q2 print (EPS is already expected to fall ≈7% YoY) or Prolia/Xgeva erosion accelerating pulls AMGN down toward the $330-$300 put-gamma support zone.

---

💡 Trading Ideas

A note before these: this print is a roll, not a signal to chase — nobody added new directional risk today. These ideas are about how you might play AMGN into earnings and the ex-dividend, independent of the roll itself.

🛡️ Conservative: Wait for Earnings, Then Decide

Do nothing until after the August 4 close. With EPS expected to decline ≈7% YoY, let the binary event pass and IV settle before committing new capital. Risk level: minimal (cash) | Skill level: beginner-friendly.

⚖️ Balanced: Defined-Risk Call Spread Through October OPEX

If you want measured upside exposure through the same October 16 window the roll targets, a bought $400 call / sold $420 call vertical caps both cost and risk while still participating if AMGN grinds toward the call-gamma cluster near $400-$440. Size small — earnings sit inside this window. Risk level: moderate, defined | Skill level: intermediate.

🚀 Aggressive: Earnings Straddle (Advanced Only)

Buying a short-dated straddle around the August 4 print bets that the actual move exceeds the ±9.5% priced into the August OPEX implied range. This is expensive, theta bleeds fast, and IV crush can cause a loss even if you're right on direction — only for traders who've managed earnings straddles before. Risk level: extreme (can lose 100% of premium) | Skill level: advanced only.

---

👥 How Different Traders Should Read This

• 🎰 YOLO Trader: There's nothing to YOLO into here — this is a boring financing roll, not a whale conviction bet. Save your ammo for the August 4 earnings reaction instead.
• 📊 Swing Trader: Watch the $310 as a reference, but trade the implied-move cone and the $400/$440 vs. $330/$300 gamma zones around earnings and the ex-dividend, not this specific roll.
• 💰 Premium Collector: The ≈9.5% implied move into August 21 OPEX (right where the old short leg lived) tells you IV is elevated into earnings — a candidate window for defined-risk premium-selling strategies once the earnings date passes and IV starts to compress.
• 🌱 Beginner Investor: This is actually a great real-world example of why options traders roll positions — to manage dividend and assignment risk on deep-ITM contracts. File it away; it's a maintenance move, not something to copy as a new trade idea.

---

⚠️ Risk Factors

• ✅ Open vs. close is RESOLVED — the roll is confirmed. August OI fell 2,217 → 491 (−1,726) while October OI rose 224 → 2,418 (+2,194). The diagonal alternative is ruled out, so the "neutral, no new risk" read stands. The only residual nuance: ≈79% of the August leg genuinely retired contracts and the remainder transferred to another holder.
• What OPRA cannot tell us: the broker/MMID, the trader's identity, whether this account has any additional stock or hedge position elsewhere, and whether this is a single trader or a coordinated desk position. We're reading a print, not a portfolio.
• Earnings risk is real and imminent. Q2 results land August 4 with consensus EPS expected to decline ≈7% YoY — a miss could pressure the stock before the rolled position even reaches its dividend-avoidance purpose.
• MariTide is a 2027 story, not a 2026 one. Don't let obesity-drug optimism drive near-term trading decisions — there's no Phase 3 data due until early next year.
• Gamma data here is thin. Unlike a heavily-traded mega-cap, AMGN's dealer gamma isn't concentrated at clean levels today — treat the gamma commentary above as directional color, not a precision map.

---

🎯 The Bottom Line

Real talk: this is not a "someone's betting $32M on AMGN" headline — it's a ≈$0.4M net-cost roll of an already-existing deep-ITM long call position, timed to sidestep Amgen's August 24 ex-dividend and the early-assignment risk that comes with holding deep-ITM calls into a dividend date. The trader isn't adding new bullish conviction — they're keeping the lights on for a position they already had.

If you own AMGN: nothing here changes your thesis. Watch the August 4 earnings print and the ±9.5% priced move around it.

If you're watching from the sidelines: don't read this roll as a signal to chase calls. If you want exposure, size for the Q2 earnings binary risk and remember MariTide's real catalyst isn't until early 2027.

Mark your calendar:

• 📅 August 4 — Q2 2026 earnings, after the close
• 📅 August 21 — the old short leg's expiration date (now closed via the roll)
• 📅 August 24 — ex-dividend date, $2.52/share
• 📅 October 16 — new expiration for the rolled long calls
• 📅 Early 2027 — MARITIME-1 Phase 3 obesity readout, the real long-term catalyst

✅ The OI update is in (July 31 pre-market) and it confirms a genuine close-and-reopen roll: August $310 open interest fell 2,217 → 491 while October $310 rose 224 → 2,418. The picture did not change — it hardened.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. The trade described here is a financing/maintenance roll, confirmed against the next-day OPRA open-interest snapshot (August leg closed, October leg opened). What the tape still cannot reveal is the desk's identity, its motive, or any offsetting position held elsewhere. Always do your own research and consider consulting a licensed financial advisor before trading.

---

About Amgen: Amgen is one of the world's largest biotechnology companies, with a diversified portfolio spanning cardiovascular, bone health, inflammation/respiratory, oncology, and rare disease, and a market cap of ≈$199 billion in the Health Care / Biotechnology-Pharmaceuticals sector.

---

Last updated: 2026-07-31 — next-day OPRA open-interest confirmed the calendar roll: Aug-21-2026 $310C CLOSED (OI 2,217 → 491, −1,726) and Oct-16-2026 $310C OPENED (OI 224 → 2,418, +2,194).